Page last updated: 2024-08-26

yttrium radioisotopes and lutetium

yttrium radioisotopes has been researched along with lutetium in 100 studies

Research

Studies (100)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.00)	18.2507
2000's	34 (34.00)	29.6817
2010's	61 (61.00)	24.3611
2020's	4 (4.00)	2.80

Authors

Authors	Studies
Cheng, R; Colcher, D; Eggensperger, D; Fordyce, W; Goeckeler, W; Kruper, WJ; Milenic, DE; Schlom, J; Schott, ME; Siler, K	1
Chen, S; Goldenberg, DM; Govindan, SV; Griffiths, GL; Hansen, HJ; Reed, L; Richel, H; Stein, R	1
Bakker, WH; Breeman, WA; de Jong, M; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Valkema, R; Visser, TJ	1
Breeman, WA; De Jong, M; Erion, JL; Krenning, EP; Visser, TJ	1
Boerman, OC; Corstens, FH; Frielink, C; Goldenberg, DM; Oyen, WJ; Postema, EJ; Raemaekers, JM	1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabahajosula, S	1
Ahlman, H; Bernhardt, P; Forssell-Aronsson, E	1
Boerman, OC; Brouwers, AH; Corstens, FH; Frielink, C; Oosterwijk, E; Oyen, WJ; van Eerd, JE	1
Bleichrodt, RP; Boerman, OC; Goldenberg, DM; Koppe, MJ; Oyen, WJ; Soede, AC; Verhofstad, AA	1
Bijster, M; De Jong, M; Konijnenberg, MW; Krenning, EP	1
Chen, J; Hinni, K; Maecke, HR; Reubi, JC; Waldherr, C; Waser, B; Zhang, H	1
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Kothari, PA; Kuji, I; Milowski, MI; Nanus, DM; Vallabhajosula, S	1
Scott, AM	1
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Milowski, MI; Nanus, DM; Vallabhajosula, S	1
Hoffman, TJ; Miao, Y; Quinn, TP	1
Daly, T; Descalle, MA; Fisher, D; Hartmann-Siantar, C; Hoffman, T; Lehmann, J; Lewis, MR; Miller, WH; Situ, PD; Smith, J; Volkert, WA	1
de Jong, M; Esser, JP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R	1
Mårtensson, L; Nilsson, R; Ohlsson, T; Senter, P; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z	1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S	1
Leemans, CR; Perk, LR; Stigter-van Walsum, M; Tijink, BM; van Dongen, GA; Visser, GW; Vosjan, MJ	1
Axworthy, DB; Buchsbaum, DJ; Carpenter, M; Chaudhuri, TR; Khazaeli, MB; LoBuglio, AF; Schultz, J; Zinn, KR	1
deHerder, WW; deJong, M; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R	1
Bernhardt, P; Forssell-Aronsson, E; Maecke, HR; Rösch, F; Uusijärvi, H	1
Forte, LR; Giblin, MF; Hoffman, TJ; Shelton, TD; Sieckman, GL; Volkert, WA	1
Fisher, DR; Miao, Y; Quinn, TP	1
Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F	1
Mather, SJ; Sosabowski, JK	1
de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R	1
Forrer, F; Maecke, HR; Mueller-Brand, J; Riedweg, I	1
Jødal, L	1
Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M	1
Chen, J; Fani, M; Forrer, F; Lohri, A; Maecke, HR; Moldenhauer, G; Müller-Brand, J; Powell, P	1
Archimandritis, SC; Bouziotis, P; Garnuszek, P; Karczmarczyk, U; Koumarianou, E; Maurin, M; Mikołajczak, R; Pawlak, D; Zikos, X	1
Bombardieri, E; Canevari, S; Coliva, A; Figini, M; Giussani, A; Luison, E; Seregni, E; Zacchetti, A	1
Agazzi, A; Aricò, D; Bodei, L; De Cicco, C; De Simone, M; Pacifici, M; Paganelli, G; Quarna, J; Sansovini, M; Sierra, ML	1
Bodei, L; Paganelli, G; Pepe, G	1
Couto, RM; De Araújo, EB; De Barboza, MF; De Souza, AA; Mengatti, J; Muramoto, E	1
Bergmann, R; Pietzsch, HJ; Schiller, E; Wunderlich, G	1
Bekonde, EB; Jamar, F; Lhommel, R; Pauwels, S; van Elmbt, L; Walrand, S	1
de Herder, WW; Krenning, EP; Kwekkeboom, DJ	1
Forrer, F; Giovacchini, G; Müller-Brand, J; Nicolas, G	1
Dabasi, G; Igaz, P; Kender, Z; Rácz, K; Reismann, P; Sréter, L	1
Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA	1
de Jong, M; Konijnenberg, MW	1
Kamali-Asl, A; Mohagheghpoor, E; Poorbaygi, H; Reza Aghamiri, SM; Sheibani, S	1
Głowa, B; Hubalewska-Dydejczyk, AB; Jabrocka-Hybel, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pach, D; Pawlak, D; Sowa-Staszczak, A; Stefańska, A; Tomaszuk, M; Trofimiuk, M	1
Asti, M; Cutler, CS; Farioli, D; Guidotti, C; Iori, M; Mayer, P; Salvo, D; Tegoni, M; Versari, A	1
Jurgilewicz, D	1
Alvarez, R; Grizzle, W; LoBuglio, A; Meredith, R; Partridge, E; You, Z	1
Baio, SM; Bodei, L; Chinol, M; Cremonesi, M; Grana, CM; Paganelli, G; Severi, S	1
Briel, M; Brunner, P; Koller, MT; Mäcke, HR; Marincek, N; Müller-Brand, J; Ng, QK; Rochlitz, C; Romer, A; Schindler, C; Villard, L; Walter, MA	1
Kwekkeboom, DJ	1
Jonsson, BA; Larsson, E; Ljungberg, M; Martensson, L; Nilsson, R; Strand, SE; Tennvall, J	1
Chen, Y; Chong, HS; Jia, F; Kang, CS; Lewis, M; Song, HA; Sun, X	1
Asti, M; Atti, G; Farioli, D; Filice, A; Iori, M; Versari, A	1
Beckford Vera, DR; Beran, M; Eigner Henke, K; Eigner, S; Leyva Montaña, R; Melichar, F	1
Bartenstein, P; Baum, RP; Bengel, FM; Biersack, HJ; Dunkelmann, S; Ezziddin, S; Gratz, KF; Haug, A; Hörsch, D; Knapp, WH; Krause, BJ; Plöckinger, U; Schümichen, C; Schwartz-Fuchs, S	1
Cwikla, J; Gut, P; Handkiewicz-Junak, D; Hubalewska-Dydejczyk, A; Jakuciński, M; Kamiński, G; Kowalska, A; Królicki, L; Kunikowska, J; Lukiewicz, A; Mikolajczak, R; Pawlak, D; Sowa-Staszczak, A; Szaluś, N	1
Chang, SJ; Chao, MM; Huang, DE; Liu, YL; Tsai, SY; Wu, J	1
Birkenfeld, B; Celler, A; Piwowarska-Bilska, H; Shcherbinin, S	1
Baechler, S; Boubaker, A; Dieudonné, A; Gardin, I; Hobbs, RF; Le Guludec, D; Lebtahi, R; Maurel, F; Sgouros, G; Wahl, RL	1
Mikolajczak, R; Parus, JL	1
Li, H; Tang, K; Wang, L; Wen, Z; Zhang, H; Zhang, Q	1
Baker, M; Fenwick, A; Ferreira, K; Keightley, J	1
Cheal, SM; Cheung, NK; Guo, HF; Larson, SM; Xu, H; Zanzonico, PB	1
Allen-Auerbach, MS; Bluemel, C; Herrmann, K; Higuchi, T; Werner, RA	1
Ahmadi, M; Bacot, S; Boturyn, D; Bourre, JC; Bozon-Petitprin, A; Broisat, A; Claron, M; Fagret, D; Gauchez, AS; Ghezzi, C; Marti-Batlle, D; Perret, P; Riou, LM; Vuillez, JP	1
Celler, A; Grimes, J	1
Balkin, ER; Fisher, DR; Green, DJ; Hernandez, A; Hylarides, MD; Kenoyer, A; Orozco, JJ; Pagel, JM; Press, OW; Shadman, M; Wilbur, DS	1
Baum, RP; Bodei, L; Cremonesi, M; Drozdov, I; Grana, CM; Kidd, M; Krenning, EP; Kwekkeboom, DJ; Lepensky, C; Modlin, IM; Paganelli, G	1
Hicks, RJ	1
Chen, Y; Chong, HS; Kang, CS; Kweon, J; Lee, H; Lewis, MR; Liu, D; Sun, X	1
Garnuszek, P; Karczmarczyk, U; Maurin, M; Mikołajczak, R; Wojdowska, W	1
Chen, Y; Chong, HS; Kang, CS; Lewis, MR; Liu, D; Ruthengael, VC; Sin, I; Song, HA; Sun, X; Wu, N; Zhong, Y	1
Bäck, TA; Booth, GC; Fisher, DR; Frayo, SL; Frost, SH; Gopal, AK; Green, DJ; Hylarides, MD; Lin, Y; Miller, BW; Orozco, JJ; Pagel, JM; Press, OW	1
Feron, O; Gallez, B; Lucas, S; Masereel, B; Michiels, C; Vander Borght, T	1
Abdülrezzak, Ü; Buyukkaya, F; Karaca, H; Kula, M; Tutuş, A	1
Baran, P; Garnuszek, P; Maurin, M; Mikołajczak, R; Pawlak, D	1
Bodei, L; Botta, F; Cremonesi, M; D'Errico, V; Ferrari, M; Fioroni, F; Grassi, E; Guerriero, F; Orecchia, R; Paganelli, G; Sarnelli, A; Strigari, L	1
Carrasquillo, JA; Chalasani, S; Cheal, SM; Cheung, NV; Fung, EK; Guo, HF; Jungbluth, A; Larson, SM; Lee, SG; O'Donoghue, J; Punzalan, B; Smith-Jones, PM; Wittrup, KD; Xu, H; Zanzonico, PB	1
Marcinkowski, R; Mollet, P; Van Holen, R; Vandenberghe, S	1
Champion, C; Hindié, E; Morgat, C; Quinto, MA; Zanotti-Fregonara, P	1
Celler, A; Esquinas, PL; Gonzalez, M; Uribe, CF	1
Filice, A; Fioroni, F; Giorgia, C; Grassi, E; Iori, M; Mostacci, D; Piccagli, V; Sara, R; Versari, A	1
Chakraborty, S; Chakravarty, R; Dash, A; Nair, KV; Rajeswari, A; Sarma, HD	1
Bodei, L; Chiti, A; Cremonesi, M; Ezziddin, S; Forrer, F; Hicks, RJ; Kidd, M; Luster, M; Modlin, IM	1
Bley, TA; Bluemel, C; Buck, AK; Fassnacht, M; Hahner, S; Heinze, B; Herrmann, K; Kroiss, M; Kropf, S; Lapa, C; Schirbel, A; Wester, HJ	1
Geramifar, P; Kamali Asl, A; Khazaee Moghadam, M; Zaidi, H	1
Carlier, T; Conti, M; Eriksson, L; Rosenqvist, G; Rothfuss, H; Sjoeholm, T; Townsend, D	1
Alenezi, SA; Dannoon, SF; Elgazzar, AH	1
Asti, M; Capponi, PC; Dreger, T; Esposizione, LR; Fioroni, F; Formisano, D; Grassi, E; Iori, M; Pitzschler, R; Rubagotti, S; Seemann, J; Versari, A	1
Arani, SS; Maraghe, MG; Mehrabi, M; Salek, N; Samani, AB; Vosoghi, S	1
Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A	1
Bodei, L; Botta, F; Chiesa, C; Cremonesi, M; Ferrari, ME; Garibaldi, C; Grana, CM; Orecchia, R; Pacilio, M; Sarnelli, A; Strigari, L; Summers, PE	1
Bednarz, B; Lee, D; Li, M; Schultz, MK	1
Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z	1
Bilha, SC; Constantin, V; Covic, A; Matovic, M; Nistor, I; Simona, V; Stefanescu, C; Stolniceanu, CR	1
Baum, RP; Hommann, M; Hörsch, D; Kaemmerer, D; Kulkarni, HR; Sehner, S; Twrznik, M	1
Chen, Y; Chong, HS; Kang, CS; Sin, I; Wang, H; Zhang, S	1
Bober, B; Brodowska-Kania, D; Kaminski, G; Kapusta, W; Kolodziej, M; Lubas, A; Saracyn, M	1

Reviews

17 review(s) available for yttrium radioisotopes and lutetium

Article	Year
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. European journal of nuclear medicine, 2001, Volume: 28, Issue:9 Topics: Humans; Indium Radioisotopes; Lutetium; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2001
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in oncology, 2003, Volume: 30, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antigens, Surface; Clinical Trials, Phase I as Topic; Cytotoxins; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Extracellular Space; Fluorescent Antibody Technique; Glutamate Carboxypeptidase II; Humans; Immunoglobulin G; Lutetium; Male; Mice; Prostatic Neoplasms; Radioimmunodetection; Radioisotopes; Treatment Outcome; Yttrium Radioisotopes	2003
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best practice & research. Clinical gastroenterology, 2005, Volume: 19, Issue:4 Topics: Animals; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Patient Selection; Pentetic Acid; Peptides, Cyclic; Quality of Life; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Somatostatin; Treatment Outcome; Yttrium Radioisotopes	2005
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. Journal of endocrinological investigation, 2005, Volume: 28, Issue:11 Suppl I Topics: Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2005
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematology/oncology clinics of North America, 2007, Volume: 21, Issue:3 Topics: Endocrine Gland Neoplasms; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Octreotide; Sensitivity and Specificity; Tomography, X-Ray Computed; Yttrium Radioisotopes	2007
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. European review for medical and pharmacological sciences, 2010, Volume: 14, Issue:4 Topics: Antineoplastic Agents; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Yttrium Radioisotopes	2010
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1 Topics: Animals; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2011
Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1 Topics: Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiotherapy; Somatostatin; Yttrium Radioisotopes	2011
Preclinical animal research on therapy dosimetry with dual isotopes. European journal of nuclear medicine and molecular imaging, 2011, Volume: 38 Suppl 1 Topics: Animals; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Indium Radioisotopes; Lutetium; Neoplasms; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Yttrium Radioisotopes	2011
Yttrium-labelled peptides for therapy of NET. European journal of nuclear medicine and molecular imaging, 2012, Volume: 39 Suppl 1 Topics: Bone Marrow; Clinical Trials as Topic; Humans; Kidney; Lutetium; Neuroendocrine Tumors; Octreotide; Peptides; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Peptide; Safety; Treatment Outcome; Yttrium Radioisotopes	2012
Beta-emitting radionuclides for peptide receptor radionuclide therapy. Current topics in medicinal chemistry, 2012, Volume: 12, Issue:23 Topics: Beta Particles; Chelating Agents; Humans; Isotope Labeling; Ligands; Lutetium; Neuroendocrine Tumors; Radioactivity; Radioisotopes; Radionuclide Imaging; Radiotherapy; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2012
Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. BioMed research international, 2013, Volume: 2013 Topics: Humans; Lutetium; Molecular Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2013
68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Annals of nuclear medicine, 2015, Volume: 29, Issue:1 Topics: Gallium Radioisotopes; Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2015
The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis. Nuclear medicine communications, 2017, Volume: 38, Issue:12 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide; Treatment Outcome; Yttrium Radioisotopes	2017
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Nuclear medicine review. Central & Eastern Europe, 2018, Volume: 21, Issue:2 Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes	2018
Correlation of dose with toxicity and tumour response to European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:13 Topics: Humans; Lutetium; Precision Medicine; Radioisotopes; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Receptors, Peptide; Yttrium Radioisotopes	2018
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nuclear medicine communications, 2020, Volume: 41, Issue:7 Topics: Humans; Isotope Labeling; Kidney; Lutetium; Neuroendocrine Tumors; Radioisotopes; Renal Insufficiency; Somatostatin; Yttrium Radioisotopes	2020

Trials

7 trial(s) available for yttrium radioisotopes and lutetium

Article	Year
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:4 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Half-Life; Humans; Indium Radioisotopes; Lutetium; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Tissue Distribution; Yttrium Radioisotopes	2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:5 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Bone Marrow; Bone Marrow Diseases; Dose-Response Relationship, Radiation; Humans; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Yttrium Radioisotopes	2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Antibodies, Monoclonal; Blood Platelets; Bone Marrow; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Lutetium; Male; Maximum Tolerated Dose; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Thrombocytopenia; Time Factors; Yttrium Radioisotopes	2005
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery, 2006, Volume: 140, Issue:6 Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes	2006
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2008, Volume: 52, Issue:4 Topics: Adult; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Octreotide; Paraganglioma; Pheochromocytoma; Staining and Labeling; Yttrium Radioisotopes	2008
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:9 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Pilot Projects; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes	2009
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Leukemia, Myeloid, Acute; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2015

Other Studies

76 other study(ies) available for yttrium radioisotopes and lutetium

Article	Year
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer, 1994, Feb-01, Volume: 73, Issue:3 Suppl Topics: Aniline Compounds; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Colonic Neoplasms; Glycoproteins; Heterocyclic Compounds; Humans; Immunotoxins; Iodine Radioisotopes; Lutetium; Metals, Rare Earth; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy; Radioisotopes; Samarium; Tissue Distribution; Transplantation, Heterologous; Yttrium Radioisotopes	1994
Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:6 Topics: Animals; Antibodies, Monoclonal; Female; Glycoproteins; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Lung Neoplasms; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy; Radioisotopes; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes	2001
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:6 Topics: Binding, Competitive; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Isotope Labeling; Kinetics; Ligands; Lutetium; Peptides; Radioisotopes; Yttrium Radioisotopes	2003
Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:4 Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Adhesion Molecules; Duodenum; Female; Femur; Humans; Iodine Radioisotopes; Kidney; Lectins; Liver; Lung; Lutetium; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Nude; Muscles; Neoplasm Transplantation; Neoplasms; Radioimmunotherapy; Radioisotopes; Rhenium; Sialic Acid Binding Ig-like Lectin 2; Spleen; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2003
Model of metastatic growth valuable for radionuclide therapy. Medical physics, 2003, Volume: 30, Issue:12 Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Division; Computer Simulation; Dose-Response Relationship, Radiation; Humans; Liver Neoplasms; Lutetium; Models, Biological; Neoplasm Staging; Prognosis; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Relative Biological Effectiveness; Rhodium; Treatment Outcome; Yttrium Radioisotopes	2003
Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:2 Topics: Animals; Antibodies, Monoclonal; Carcinoma, Renal Cell; Humans; Iodine Radioisotopes; Isotope Labeling; Kidney Neoplasms; Lutetium; Mice; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Rhenium; Tissue Distribution; Yttrium Radioisotopes	2004
Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:7 Topics: Animals; Antibodies, Monoclonal; Colorectal Neoplasms; Injections, Intraperitoneal; Injections, Intravenous; Iodine Radioisotopes; Lutetium; Male; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Organ Specificity; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Reproducibility of Results; Rhenium; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes	2004
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:7 Topics: Animals; Body Burden; Computer Simulation; Drug Evaluation, Preclinical; Femoral Neoplasms; Indium Radioisotopes; Lutetium; Metabolic Clearance Rate; Models, Biological; Octreotide; Organ Specificity; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Wistar; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes	2004
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer research, 2004, Sep-15, Volume: 64, Issue:18 Topics: Animals; Bombesin; Drug Stability; Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes	2004
Radioimmunotherapy of prostate cancer: does tumor size matter? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-20, Volume: 23, Issue:21 Topics: Antibodies, Monoclonal; Humans; Lutetium; Male; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Yttrium Radioisotopes	2005
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nuclear medicine and biology, 2005, Volume: 32, Issue:5 Topics: alpha-MSH; Animals; Female; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Radiopharmaceuticals; Yttrium Radioisotopes	2005
Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer biotherapy & radiopharmaceuticals, 2005, Volume: 20, Issue:4 Topics: Animals; Copper Radioisotopes; Disease Models, Animal; Holmium; Lutetium; Mice; Mice, Nude; Models, Statistical; Models, Theoretical; Promethium; Radioimmunotherapy; Radioisotopes; Radiometry; Radiopharmaceuticals; Rhenium; Tissue Distribution; Yttrium Radioisotopes	2005
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Animals; Antibodies, Monoclonal; Biotin; Body Weight; Brain; Chelating Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Leukocytes; Lutetium; Maximum Tolerated Dose; Platelet Count; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Yttrium Radioisotopes	2005
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:11 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lutetium; Metabolic Clearance Rate; Mice; Mice, Nude; Organ Specificity; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes; Zirconium	2005
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-15, Volume: 11, Issue:22 Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Neoplasm; Biotin; Cell Line, Tumor; Colonic Neoplasms; Glycoproteins; Humans; Indium Radioisotopes; Injections, Intraperitoneal; Iodine Radioisotopes; Lutetium; Mice; Mice, Nude; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Streptavidin; Survival Analysis; Time Factors; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2005
Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:5 Topics: Electrons; Holmium; Humans; Lanthanoid Series Elements; Lutetium; Positron-Emission Tomography; Promethium; Radioisotopes; Radiometry; Terbium; Thulium; Time Factors; Yttrium Radioisotopes	2006
In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers. Nuclear medicine and biology, 2006, Volume: 33, Issue:4 Topics: Animals; Bacterial Toxins; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Stability; Escherichia coli; Female; Hot Temperature; Humans; Isotope Labeling; Lutetium; Metabolic Clearance Rate; Mice; Mice, Inbred ICR; Natriuretic Peptides; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Cell Surface; Tissue Distribution; Yttrium Radioisotopes	2006
Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nuclear medicine and biology, 2006, Volume: 33, Issue:6 Topics: alpha-MSH; Animals; Kidney; Lutetium; Melanoma; Mice; Mice, Inbred C57BL; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes	2006
Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nature protocols, 2006, Volume: 1, Issue:2 Topics: Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Isotope Labeling; Lutetium; Metals; Molecular Structure; Peptides; Yttrium Radioisotopes	2006
Beta emitters and radiation protection. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:2 Topics: Aluminum; Beta Particles; Half-Life; Humans; Iodine Radioisotopes; Lead; Lutetium; Polymethyl Methacrylate; Radiation Monitoring; Radiation Protection; Radioisotopes; Specimen Handling; Yttrium Radioisotopes	2009
[Peptide receptor radionuclide therapy of neuroendocrine tumors]. Ugeskrift for laeger, 2009, Mar-23, Volume: 171, Issue:13 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes	2009
Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation. Nuclear medicine and biology, 2009, Volume: 36, Issue:6 Topics: Animals; Biological Transport; Bombesin; Cell Line, Tumor; Cell Survival; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Male; Mice; Radiopharmaceuticals; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes	2009
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nuclear medicine and biology, 2009, Volume: 36, Issue:7 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Carrier Proteins; Cell Line, Tumor; Female; Folate Receptors, GPI-Anchored; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Isotope Labeling; Lutetium; Maximum Tolerated Dose; Mice; Neoplasms; Radioimmunotherapy; Radioisotopes; Receptors, Cell Surface; Time Factors; Tissue Distribution; Transplantation, Heterologous; Tumor Burden; Yttrium Radioisotopes	2009
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:6 Topics: Adult; Aged; B-Lymphocytes; Colonic Neoplasms; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Lung Neoplasms; Lutetium; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes	2009
In vivo comparative study of hydroxyapatite labeled with different radioisotopes: evaluation of the scintigraphic images. Cellular and molecular biology (Noisy-le-Grand, France), 2010, May-10, Volume: 56, Issue:2 Topics: Animals; Beta Particles; Colloids; Durapatite; Gamma Rays; Hindlimb; Inflammation; Injections, Intra-Articular; Lutetium; Particle Size; Radioisotopes; Radionuclide Imaging; Rats; Rats, Wistar; Samarium; Tissue Distribution; Whole Body Imaging; Yttrium Radioisotopes	2010
Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM). Nuclear medicine and biology, 2010, Volume: 37, Issue:8 Topics: Animals; Drug Stability; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kinetics; Lutetium; Male; Microspheres; Rats; Rats, Wistar; Serum Albumin; Yttrium Radioisotopes	2010
4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:12 Topics: Humans; Image Interpretation, Computer-Assisted; Kidney Cortex; Liver; Lutetium; Phantoms, Imaging; Radiometry; Radionuclide Imaging; Receptors, Peptide; Silicates; Yttrium Radioisotopes	2010
[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients]. Orvosi hetilap, 2011, Mar-06, Volume: 152, Issue:10 Topics: Adult; Aged; Female; Humans; Hungary; Indium Radioisotopes; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Radioisotopes; Radiotherapy; Receptors, Somatostatin; Remission Induction; Yttrium Radioisotopes	2011
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer, 2011, Apr-01, Volume: 117, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes	2011
Production of glass microspheres comprising 90Y and (177)Lu for treating of hepatic tumors with SPECT imaging capabilities. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2011, Volume: 69, Issue:10 Topics: Humans; Liver Neoplasms; Lutetium; Microspheres; Radioisotopes; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes	2011
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 102, Issue:1 Topics: Aged; Diagnostic Imaging; Disease Progression; Female; Humans; Lutetium; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Receptors, Peptide; Statistics, Nonparametric; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes	2012
Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions. Nuclear medicine and biology, 2012, Volume: 39, Issue:4 Topics: Cations; Isotope Labeling; Lutetium; Octreotide; Organometallic Compounds; Radiochemistry; Reference Standards; Yttrium Radioisotopes	2012
Report from the 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT), Bad Berka (Germany), June 23-26, 2011. Nuclear medicine review. Central & Eastern Europe, 2011, Volume: 14, Issue:2 Topics: Gallium Radioisotopes; Germanium; Germany; Humans; Lutetium; Molecular Targeted Therapy; Multimodal Imaging; Nuclear Medicine; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Tomography, X-Ray Computed; Yttrium Radioisotopes	2011
Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:1 Topics: Adult; Aged; Animals; Antibodies, Neoplasm; Disease-Free Survival; Female; Humans; Immunotoxins; Infusions, Parenteral; Lutetium; Mice; Middle Aged; Ovarian Neoplasms; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes	2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioisotopes; Somatostatin; Yttrium Radioisotopes	2012
Therapy: Neuroendocrine cancer--are two radionuclides better than one? Nature reviews. Endocrinology, 2012, May-01, Volume: 8, Issue:6 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Somatostatin; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2012
Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs. Medical physics, 2012, Volume: 39, Issue:7 Topics: Animals; Antibodies, Monoclonal; Biomimetic Materials; Bone Marrow; Computer Simulation; Dose-Response Relationship, Radiation; Hematopoietic System; Lutetium; Metabolic Clearance Rate; Models, Biological; Models, Statistical; Monte Carlo Method; Phantoms, Imaging; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Rats; Statistics as Topic; Yttrium Radioisotopes	2012
Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy. Bioconjugate chemistry, 2012, Sep-19, Volume: 23, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Chelating Agents; Drug Evaluation, Preclinical; Kinetics; Ligands; Lutetium; Radioimmunotherapy; Trastuzumab; Yttrium Radioisotopes	2012
Semiautomated labelling and fractionation of yttrium-90 and lutetium-177 somatostatin analogues using disposable syringes and vials. Nuclear medicine communications, 2012, Volume: 33, Issue:11 Topics: Automation; Disposable Equipment; Dose Fractionation, Radiation; Drug Compounding; Isotope Labeling; Lutetium; Quality Control; Radiopharmaceuticals; Somatostatin; Syringes; Yttrium Radioisotopes	2012
(177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; ErbB Receptors; Humans; Immunoconjugates; Isotope Labeling; Lutetium; Male; Mice; Radioimmunotherapy; Radioisotopes; Rats; Rats, Wistar; Receptor, ErbB-2; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2013
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Radioisotopes; Receptors, Somatostatin; Registries; Yttrium Radioisotopes	2013
Polish experience in Peptide receptor radionuclide therapy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2013
Dose point kernel simulation for monoenergetic electrons and radionuclides using Monte Carlo techniques. Radiation protection dosimetry, 2012, Volume: 152, Issue:1-3 Topics: Algorithms; Cell Nucleus; Computer Simulation; Cytoplasm; Electrons; Humans; Lutetium; Models, Statistical; Monte Carlo Method; Radiation Dosage; Radiation Monitoring; Radioisotopes; Radiometry; Reproducibility of Results; Rhodium; Software; Yttrium Radioisotopes	2012
Quantitative SPECT/CT reconstruction for ¹⁷⁷Lu and ¹⁷⁷Lu/⁹⁰Y targeted radionuclide therapies. Physics in medicine and biology, 2012, Sep-21, Volume: 57, Issue:18 Topics: Humans; Image Processing, Computer-Assisted; Lutetium; Multimodal Imaging; Phantoms, Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Yttrium Radioisotopes	2012
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:2 Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Imaging, Three-Dimensional; Iodine Radioisotopes; Liver Neoplasms; Lutetium; Lymphoma, Non-Hodgkin; Microspheres; Models, Statistical; Monte Carlo Method; Neuroendocrine Tumors; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Dosage; Yttrium Radioisotopes	2013
Comparison of ⁹⁰Y and ¹⁷⁷Lu measurement capability in UK and European hospitals. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2014, Volume: 87 Topics: Europe; Hospitals; Lutetium; Reference Standards; United Kingdom; Yttrium Radioisotopes	2014
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Molecular cancer therapeutics, 2014, Volume: 13, Issue:7 Topics: Animals; Antibodies, Bispecific; Drug Evaluation, Preclinical; Female; Gangliosides; Humans; Immunoglobulin Fragments; Immunoglobulin G; Lutetium; Mice; Mice, Nude; Octreotide; Organometallic Compounds; Radioimmunotherapy; Radiopharmaceuticals; Random Allocation; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2014
Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:2 Topics: Animals; Cell Line, Tumor; Humans; Integrin alphaVbeta3; Lutetium; Mice; Mice, Nude; Neoplasms, Experimental; Peptides, Cyclic; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2015
Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques. Medical physics, 2014, Volume: 41, Issue:9 Topics: Algorithms; Computer Simulation; Female; Humans; Iodine Radioisotopes; Kidney; Liver; Lutetium; Male; Models, Biological; Monte Carlo Method; Neoplasms; Niacinamide; Octreotide; Radiation Dosage; Radiopharmaceuticals; Software; Technetium; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes	2014
In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model. Cancer research, 2014, Oct-15, Volume: 74, Issue:20 Topics: Animals; Cell Line, Tumor; Female; Immunoconjugates; Leukemia; Luminescent Measurements; Lutetium; Mice; Phantoms, Imaging; Radionuclide Imaging; Radiopharmaceuticals; Spleen; Tissue Distribution; Yttrium Radioisotopes	2014
The difference between medicine and magic is that magicians know what they are doing. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1 Topics: Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes	2015
Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu. Nuclear medicine and biology, 2015, Volume: 42, Issue:3 Topics: Animals; Cell Line, Tumor; Chelating Agents; Chemistry Techniques, Synthetic; Drug Stability; Glioblastoma; Heterocyclic Compounds; Humans; Isotope Labeling; Kinetics; Lutetium; Mice; Molecular Targeted Therapy; Oligopeptides; Tissue Distribution; Yttrium Radioisotopes	2015
Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation. Current radiopharmaceuticals, 2015, Volume: 8, Issue:1 Topics: Chelating Agents; Drug Compounding; Freeze Drying; Humans; Immunotoxins; Lutetium; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes	2015
Synthesis and comparative biological evaluation of bifunctional ligands for radiotherapy applications of (90)Y and (177)Lu. Bioorganic & medicinal chemistry, 2015, Mar-01, Volume: 23, Issue:5 Topics: Animals; Ligands; Lutetium; Mice; Radiotherapy; Tissue Distribution; Yttrium Radioisotopes	2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PloS one, 2015, Volume: 10, Issue:3 Topics: Animals; Antigens, CD20; Beta Particles; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Humans; Immunoconjugates; Lutetium; Lymphoma; Mice; Mice, Nude; Radioimmunotherapy; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2015
Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts. Computational and mathematical methods in medicine, 2015, Volume: 2015 Topics: Algorithms; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Humans; Iodine Radioisotopes; Lung; Lung Neoplasms; Lutetium; Models, Statistical; Monte Carlo Method; Nanomedicine; Neoplasms; Radiation Pneumonitis; Radioimmunotherapy; Radioisotopes; Radiotherapy Planning, Computer-Assisted; Rhenium; Yttrium Radioisotopes	2015
PET/CT and Bremsstrahlung Imaging After 90Y DOTANOC Therapy for Rectal Net With Liver Metastases. Clinical nuclear medicine, 2015, Volume: 40, Issue:10 Topics: Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Yttrium Radioisotopes	2015
The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y. Nuclear medicine review. Central & Eastern Europe, 2015, Volume: 18, Issue:2 Topics: Chemical Phenomena; Chemistry Techniques, Synthetic; Drug Stability; Gallium Radioisotopes; Gastrins; Heterocyclic Compounds, 1-Ring; Isotope Labeling; Lutetium; Yttrium Radioisotopes	2015
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2017, Volume: 61, Issue:2 Topics: Adult; Algorithms; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Models, Biological; Neuroendocrine Tumors; Organs at Risk; Radioisotopes; Radiometry; Radiotherapy; Receptors, Peptide; Yttrium Radioisotopes	2017
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:5 Topics: Animals; Antibodies, Bispecific; Antibody Affinity; Colorectal Neoplasms; Immunoconjugates; Immunoglobulin G; Lutetium; Membrane Glycoproteins; Mice; Radioimmunotherapy; Radiopharmaceuticals; Single-Chain Antibodies; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2016
Sub-millimetre DOI detector based on monolithic LYSO and digital SiPM for a dedicated small-animal PET system. Physics in medicine and biology, 2016, Mar-07, Volume: 61, Issue:5 Topics: Animals; Lutetium; Mice; Photons; Positron-Emission Tomography; Radiation Dosage; Sensitivity and Specificity; Silicates; Yttrium Radioisotopes	2016
Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:5 Topics: Beta Particles; Humans; Indium Radioisotopes; Lutetium; Monte Carlo Method; Neoplasm Micrometastasis; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Terbium; Tumor Burden; Yttrium Radioisotopes	2016
Characteristics of Bremsstrahlung emissions of (177)Lu, (188)Re, and (90)Y for SPECT/CT quantification in radionuclide therapy. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 2016, Volume: 32, Issue:5 Topics: Computer Simulation; Humans; Lutetium; Monte Carlo Method; Phantoms, Imaging; Positron-Emission Tomography; Radioisotopes; Rhenium; Single Photon Emission Computed Tomography Computed Tomography; Water; Yttrium Radioisotopes	2016
Skin dose saving of the staff in 90Y/177Lu peptide receptor radionuclide therapy with the automatic dose dispenser. Nuclear medicine communications, 2016, Volume: 37, Issue:10 Topics: Automation; Beta Particles; Chemistry; Fingers; Humans; Lutetium; Occupational Exposure; Physicians; Radiation Dosage; Radiation Protection; Receptors, Peptide; Skin; Thermoluminescent Dosimetry; Yttrium Radioisotopes	2016
(90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation. Journal of labelled compounds & radiopharmaceuticals, 2016, Volume: 59, Issue:9 Topics: Animals; Cell Line, Tumor; Cetuximab; Drug Compounding; Immunoconjugates; Isotope Labeling; Lutetium; Mice; Molecular Imaging; Positron-Emission Tomography; Radiochemistry; Tissue Distribution; Yttrium Radioisotopes	2016
Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocrine-related cancer, 2016, Volume: 23, Issue:8 Topics: Hematologic Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2016
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. Clinical nuclear medicine, 2017, Volume: 42, Issue:1 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Coordination Complexes; Female; Gallium Radioisotopes; Humans; Lutetium; Male; Middle Aged; Patient Selection; Peptides; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Radioisotopes; Radionuclide Imaging; Radiotherapy; Receptors, CXCR4; Yttrium Radioisotopes	2017
Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study. Cancer biotherapy & radiopharmaceuticals, 2016, Volume: 31, Issue:10 Topics: Algorithms; Bone Neoplasms; Computer Simulation; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Monte Carlo Method; Organ Specificity; Phosphorus Radioisotopes; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Planning, Computer-Assisted; Water; Yttrium Radioisotopes	2016
Characterization of Physics in medicine and biology, 2017, 05-07, Volume: 62, Issue:9 Topics: Background Radiation; Lutetium; Photons; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Yttrium Radioisotopes	2017
Labelling of Contrast media & molecular imaging, 2017, Volume: 2017 Topics: Automation; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Radiation Exposure; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Yttrium Radioisotopes	2017
Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation. Current radiopharmaceuticals, 2018, Volume: 11, Issue:2 Topics: Ablation Techniques; Animals; Bone Marrow; Femur; Lutetium; Mice; Models, Biological; Organophosphorus Compounds; Radiation Dosage; Radioisotopes; Rats, Wistar; Samarium; Tissue Distribution; Yttrium Radioisotopes	2018
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiation research, 2018, Volume: 190, Issue:3 Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes	2018
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjugate chemistry, 2018, 09-19, Volume: 29, Issue:9 Topics: Animals; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2018
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. Annals of surgery, 2021, 07-01, Volume: 274, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2021
Pyridine-containing octadentate ligand NE3TA-PY for formation of neutral complex with Journal of inorganic biochemistry, 2021, Volume: 221 Topics: Chelating Agents; Coordination Complexes; Density Functional Theory; Drug Stability; Humans; Isotope Labeling; Ligands; Lutetium; Models, Chemical; Pyridines; Radioisotopes; Radiopharmaceuticals; Yttrium Radioisotopes	2021
Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. Nuclear medicine review. Central & Eastern Europe, 2022, Volume: 25, Issue:1 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Receptors, Peptide; Yttrium Radioisotopes	2022